Xlife Sciences AG (XLS) | WebDisclosure

PRESS RELEASE

published on 11/28/2025 at 13:10, 7 months 10 days ago

Xlife Sciences AG Provides Update on VERAXA Biotech AG’s NASDAQ Listing Process Following U.S. Government Shutdown
Xlife Sciences AG updates on VERAXA Biotech AG's NASDAQ listing process post U.S. Government Shutdown, SEC responds to Form F-4 filing, progress towards business combination with Voyager Acquisition Corp

Nasdaq SEC Xlife Sciences AG VERAXA Biotech AG Voyager Acquisition Corp.
BRIEF

published on 10/16/2025 at 07:05, 8 months 23 days ago

Xlife Sciences AG publie son rapport ESG 2024 mettant en avant la croissance durable

Croissance Durable Responsabilité Sociale Impact Environnemental Xlife Sciences Rapport ESG 2024
BRIEF

published on 10/16/2025 at 07:05, 8 months 23 days ago

Xlife Sciences AG Releases 2024 ESG Report Highlighting Sustainable Growth

Environmental Impact Social Responsibility Sustainable Growth Xlife Sciences ESG Report 2024
PRESS RELEASE

published on 10/16/2025 at 07:00, 8 months 23 days ago

Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core
Xlife Sciences AG publishes 2024 ESG Report showcasing sustainable value creation through integrating ESG principles into corporate strategy and portfolio management in life sciences sector

Life Sciences Xlife Sciences AG ESG Principles Sustainable Value Creation 2024 ESG Report
BRIEF

published on 09/23/2025 at 07:05, 9 months 15 days ago

Xlife Sciences AG Focuses on VERAXA's NASDAQ Listing in H1 2025

Financial Performance Nasdaq Listing Global Partnerships Xlife Sciences Biotech Expansion
BRIEF

published on 09/23/2025 at 07:05, 9 months 15 days ago

Xlife Sciences AG se concentre sur l'introduction de VERAXA au NASDAQ au premier semestre 2025

Performance Financière Partenariats Mondiaux Xlife Sciences Cotation Au Nasdaq Expansion Biotechnologique
PRESS RELEASE

published on 09/23/2025 at 07:00, 9 months 15 days ago

Xlife Sciences AG Half-Year Report 2025: Focus on VERAXA Biotech AG’s NASDAQ Listing and Internationalization
Xlife Sciences AG released its Half-Year Report 2025 with focus on VERAXA Biotech AG's NASDAQ listing and internationalization. Operational and financial highlights were shared along with clear priorities for H2 2025

Nasdaq Listing Xlife Sciences AG Internationalization VERAXA Biotech AG Half-Year Report 2025
BRIEF

published on 07/17/2025 at 07:05, 11 months 22 days ago

VERAXA Biotech AG progresse vers la cotation au NASDAQ grâce au dépôt du formulaire F-4

Cotation Au Nasdaq VERAXA Biotech Regroupement D'entreprises Dépôt Du Formulaire F-4 Thérapeutiques Oncologiques
BRIEF

published on 07/17/2025 at 07:05, 11 months 22 days ago

VERAXA Biotech AG Advances Toward NASDAQ Listing with Form F-4 Filing

Nasdaq Listing Business Combination Oncology Therapeutics VERAXA Biotech Form F-4 Filing
PRESS RELEASE

published on 07/17/2025 at 07:00, 11 months 22 days ago

Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4
Xlife Sciences AG's portfolio company VERAXA Biotech AG takes a key step towards NASDAQ listing with the filing of Form F-4, signaling continued momentum and billion-dollar valuation in the public market journey

Nasdaq Listing Business Combination Xlife Sciences AG VERAXA Biotech AG Form F-4

Published on 07/08/2026 at 16:45, 2 hours 46 minutes ago

Change Of Record Date for Special Meeting
Published on 07/08/2026 at 15:25, 4 hours 6 minutes ago

Rockhaven Announces Granting of Incentive Stock Options
Published on 07/08/2026 at 15:00, 4 hours 31 minutes ago

Karbon-X Announces Strategic Partnership to Evaluate Kenya BioHub Initiative
Published on 07/08/2026 at 15:00, 4 hours 31 minutes ago

GameSquare's Stream Hatchet Publishes Esports Live Streaming Trends Report
Published on 07/08/2026 at 14:30, 5 hours 1 minute ago

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

View all ACCESSWIRE

Published on 07/08/2026 at 18:52, 38 minutes ago

namR: PRONONCÉ DE LA LIQUIDATION JUDICIAIRE DE LA SOCIÉTÉ SA NAM.R
Published on 07/08/2026 at 18:45, 45 minutes ago

EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma publishes preliminary Q3 key figures and raises 2026 revenue and earnings guidance
Published on 07/08/2026 at 18:17, 1 hour 13 minutes ago

Dividend announcement
Published on 07/08/2026 at 18:16, 1 hour 14 minutes ago

Kaufman & Broad SA: 2026 FIRST HALF RESULTS
Published on 07/08/2026 at 18:16, 1 hour 14 minutes ago

Kaufman & Broad SA: RESULTATS DU 1ER SEMESTRE 2026

View all EQS

Published on 07/08/2026 at 18:30, 1 hour 1 minute ago

Suspension of the liquidity contract
Published on 07/08/2026 at 18:30, 1 hour 1 minute ago

Suspension du contrat de liquidité
Published on 07/08/2026 at 18:00, 1 hour 31 minutes ago

464 M€ DE NOUVEAUX FINANCEMENTS POUR SOUTENIR LA CROISSANCE DE FREY
Published on 07/08/2026 at 18:00, 1 hour 31 minutes ago

€464 MILLION OF NEW FINANCING TO SUPPORT FREY'S GROWTH
Published on 07/08/2026 at 17:45, 1 hour 46 minutes ago

Déclaration des droits de vote à fin juin 2026

View all LES ECHOS COMFI WIRE

News